[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355956-105":59,"doc-detail-355956-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","gastric-cancer-organoids-mechanistic-insights-drug-discovery-and-translational-advances-in-precision-medicine-review-article","Gastric Cancer Organoids - Mechanistic Insights, Drug Discovery, and Translational Advances in Precision Medicine - Review Article","","Significant advances in localized gastric cancer treatment have been driven by early screening, improved diagnostics, surgeries, and adjuvant chemotherapy, yet personalized therapy remains debated. This review presents gastric cancer organoid (GCO) models for studying cancer mechanisms, drug discovery, and precision medicine, emphasizing simulation of the tumor microenvironment, uncovering cellular heterogeneity, and evaluating drug responses. It highlights CRISPR/Cas9 integration for target identification and clinical translation, and outlines future directions for optimized therapeutic strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/gastric-cancer-organoids-mechanistic-insights-drug-discovery-and-translational-advances-in-precision-medicine-review-article/355956/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/gastric-cancer-organoids-mechanistic-insights-drug-discovery-and-translational-advances-in-precision-medicine-review-article/355956.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role do gastric cancer organoid (GCO) models play in precision medicine?","Question",{"text":112,"@type":113},"GCO models are used to study cancer mechanisms and to support precision medicine by simulating the tumor microenvironment, revealing cell heterogeneity, and assessing drug responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does CRISPR/Cas9 gene editing enhance research using GCOs?",{"text":117,"@type":113},"Integrating CRISPR/Cas9 with GCOs enables identification of new drug targets and strengthens pathways for clinical applications in precision medicine.",{"name":119,"@type":110,"acceptedAnswer":120},"Why does gastric cancer organoid research matter given the limitations of traditional models?",{"text":121,"@type":113},"Traditional and 2D models do not reproduce patient tumors’ in-situ biological features or key tumor microenvironment elements, limiting accurate prediction of proliferation, differentiation, and drug resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355956,1790430547,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","J Gastric Cancer. 2026 Jul;26(3):345-377 [https://doi.org/10.5230/jgc.2026.26.e25](https://doi.org/10.5230/jgc.2026.26.e25)[ ](https://doi.org/10.5230/jgc.2026.26.e25)pISSN 2093-582X·eISSN 2093-5641  \nReview Article  \nReceived: Oct 28, 2025  \nRevised: Feb 18, 2026  \nAccepted: Mar 4, 2026  \nPublished online: Apr 27, 2026  \nCorrespondence to  \nYonghong Li  \nNHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor and Institute of Clinical Research and Translational Medicine, Gansu Provincial Hospital, 204 Donggang West Rd, Lanzhou 730000, China.  \nEmail: [haifenglyh@126.com](haifenglyh@126.com)  \n*Na Liu, Yan Zhang, and Yao Liu  \ncontributed as equally as co-first authors.  \nCopyright © 2026. Korean Gastric Cancer Association  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://creativecommons.org/licenses/](https://creativecommons.org/licenses/)[ ](https://creativecommons.org/licenses/)[by-nc/4.0](by-nc/4.0)) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nNa Liu   \n[https://orcid.org/0009-0006-9169-8046](https://orcid.org/0009-0006-9169-8046)  \nYan Zhang   \n[https://orcid.org/0009-0003-4192-7160](https://orcid.org/0009-0003-4192-7160)  \nYao Liu   \n[https://orcid.org/0009-0002-7869-2898](https://orcid.org/0009-0002-7869-2898)  \nXiao Dong   \n[https://orcid.org/0009-0000-8290-860X](https://orcid.org/0009-0000-8290-860X)  \nYu Li   \n[https://orcid.org/0009-0005-2545-6025](https://orcid.org/0009-0005-2545-6025)  \nGastric Cancer Organoids: Mechanistic Insights, Drug Discovery, and Translational Advances in Precision Medicine  \nNa Liu  1,*, Yan Zhang  1,*, Yao Liu  1,*, Xiao Dong  1, Yu Li  1, Jinrui Geng  1, Yonghong Li  1,2,3  \n1Gansu University of Chinese Medicine, Lanzhou, China  \n2 NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor, Gansu Provincial Hospital, Lanzhou, China  \n3 Institute of Clinical Research and Translational Medicine, Gansu Provincial Hospital, Lanzhou, China  \nABSTRACT  \nSignificant advances in the treatment of localized gastric cancer have been achieved through early screening, improved diagnostic techniques, surgeries, and adjuvant chemotherapy; however, the need for personalized treatment remains under debate. This review highlights the use of gastric cancer organoid (GCO) models to study cancer mechanisms, drug discovery, and precision medicine, focusing on their ability to simulate the tumor microenvironment, reveal cell heterogeneity, and assess drug responses. In particular, the integration of CRISPR/Cas9 gene editing with GCOs provides a powerful platforms for identifying new drug targets and supporting clinical applications in precision medicine. This review also explores the potential of these organoids in future research, particularly in optimizing treatment strategies and developing personalized therapies, thus offering new directions for precision treatment of gastric cancer.  \nKeywords: Gastric cancer; Organoids; Precision medicine; Drug screening  \nINTRODUCTION  \nGastric cancer remains a major global health challenge due to its high incidence,  \nmortality, and complex clinical management. According to the International Agency for Research on Cancer GLOBOCAN 2024 report, approximately 1.24 million new cases and 790,000 deaths occur annually, with Asia accounting for 56% of cases, largely owing to Helicobacter pylori infection, dietary factors, and genetic predisposition [1] . Despite advances in multimodal treatments, including surgery, chemotherapy (S-1 plus oxaliplatin/ capecitabine plus oxaliplatin), targeted therapy (Claudin18.2 and human epidermal growth factor receptor 2 [HER2] agents), and immune checkpoint inhibitors (ICIs) [2-5], the 5-year survival rate remains below 10% . This poor outcome is largely attributed to the pronounced heterogeneity of gastric cancer at the molecular,","cbCaifwJS1GlFRl3","https://ap.wps.com/l/cbCaifwJS1GlFRl3","pdf",2338311,33,"English","# Introduction\n## Gastric cancer challenges and heterogeneity\n# Organoid models in precision medicine\n## Simulating tumor microenvironment and heterogeneity\n## Drug response assessment\n# CRISPR/Cas9 integration and translational advances\n## Identifying drug targets\n## Supporting clinical applications\n# Future directions","[{\"question\":\"What role do gastric cancer organoid (GCO) models play in precision medicine?\",\"answer\":\"GCO models are used to study cancer mechanisms and to support precision medicine by simulating the tumor microenvironment, revealing cell heterogeneity, and assessing drug responses.\"},{\"question\":\"How does CRISPR/Cas9 gene editing enhance research using GCOs?\",\"answer\":\"Integrating CRISPR/Cas9 with GCOs enables identification of new drug targets and strengthens pathways for clinical applications in precision medicine.\"},{\"question\":\"Why does gastric cancer organoid research matter given the limitations of traditional models?\",\"answer\":\"Traditional and 2D models do not reproduce patient tumors’ in-situ biological features or key tumor microenvironment elements, limiting accurate prediction of proliferation, differentiation, and drug resistance.\"}]","Gastric Cancer Organoids - Mechanistic Insights, Drug Discovery, and Translational Advances in Precision Medicine - Review Article | PDF",1790121956,83,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fce74edd76336004dc6baa7a7b651310.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a971b2e4d663e9afd87ff07003fb085.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e8813c27125be086d8a9dcb482fb9e6.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3286441304de839bb18385b3ba03dd3f.webp",980,1306]